Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
OncoSil Medical Ltd ( (AU:OSL) ) has shared an announcement.
OncoSil Medical Ltd addressed compliance queries from the ASX regarding its involvement in the PANCOSIL study conducted by Amsterdam University Medical Centre. The study focused on the feasibility of using OncoSil™ for treating non-progressive locally advanced pancreatic cancer. OncoSil provided doses and funding for the study, but the data was owned by Amsterdam UMC. The company faced challenges in meeting disclosure obligations due to a lack of prior access to the study data, leading to a trading halt to analyze the results. OncoSil has since implemented additional training for its executive team to prevent future oversights.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
More about OncoSil Medical Ltd
OncoSil Medical Ltd is a company operating in the medical industry, focusing on the development of innovative medical devices. Its primary product is OncoSil™, a brachytherapy device designed for the treatment of pancreatic cancer. The company is involved in clinical trials and research collaborations to advance its product offerings and enhance its market presence.
Average Trading Volume: 27,407
Technical Sentiment Signal: Sell
Current Market Cap: A$28.99M
Learn more about OSL stock on TipRanks’ Stock Analysis page.